Product Name:
CK1d-pT347
Product Number:
ab-pk924
Target Full Name: Casein kinase 1-delta
Target Alias: CSNK1D; Casein kinase 1, delta; CK1-delta; CKId; EC 2.7.11.1; HCKID; KC1D; Kinase CK1-delta
Product Type Specific: CK1d protein kinase phosphosite-specific antibody
Antibody Code: PK924
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T347
Protein UniProt: P48730
Protein SigNET: CK1d
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human CK1d
Antibody Immunogen Sequence: C(βA)TPL(pT)PTSH
Antibody Immunogen Description: Corresponds to amino acid residues T344 to H351. T347 phosphorylation stimulates phosphotransferase activity. This is one of the major in vivo phosphorylation sites in CK1d (≥18 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.85 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Dog | Mouse | Frog | Zebra fish.
Related Product 1: CK1d T176 phosphorylation antibody (Cat. No.: AB-PK923)
Related Product 2: CK1d S370 phosphorylation antibody (Cat. No.: AB-PK922)
Scientific Background: CK1-delta (CSNK1D) is a 49-54 kDa protein-serine/threonine kinase of the CK1 group and CK1 family. It acts as a monomer and functions as part of the circadian core oscillator, which includes the CRY proteins, CLOCK, or NPAS2, BMAL1 or BMAL2, CSNK1D and/or CSNK1E, TIMELESS and the PER proteins. It interacts directly with PER1 and PER2, which may lead to their degradation, as well as with DBNDD2. Several loss-of-function mutations in the CSNK1D gene have been identified in advanced sleep phase syndrome, advanced sleep-phase syndrome, familial, 2, and familial advanced sleep phase syndrome 1 patients. These include a T44A substitution mutation, and a H46R substitution mutation. The T44A mutation occurs at a highly conserved residue that is found in the casein kinase 1 protein from Drosphila through mammals. The T44A mutant CSNK1D protein displays significantly reduced kinase catalytic activity compared to the wildtype protein. Similarly, the H46R residue also occurs at a highly conserved residue and has been shown to reduce the kinase catalytic activity of the H46R mutant CSNK1D protein by 53% compared to the wildtype protein. Thee ASPS phenotype is associated with a loss-of-function in the catalytic activity of the CSNK1D protein. In animal studies, Drosophila carrying the T44A mutation displayed lengthened circadian cycles. In contrast, mice carrying the same mutation display shortened circadian cycles and a similar phenotype to human advanced sleep phase syndrome. In addition, overexpression of the CSNK1D gene in the forebrain and striatum of mice results in hyperactivity, decreased anxiety, increased impulsivity, and defective nesting behaviours, potential due to abnormal circadian rythyms. Furthermore, these mice showed paradoxical responses to the injection of dopamine receptor agonists into the brain. In addition, CSNK1D overexpression is associated with decreased expression of the dopamine receptors D1 and D2 in the affected brain regions, indicating a role for the protein in the modulation of dopaminergic signalling in the brain. Familial advanced sleep phase syndrome (FASPS) is a sleep disorder characterized by the abnormal alteration of the circadian rhythym. Symptoms include falling asleep in the early evening (6:00-8:00 pm) and waking up early in the morning (e.g. 3:00 am). It is primarily located in the cytoplasm, but also found in the nucleus and centrosomes. CK1d phosphorylates Dishevelled (Dvl) and beta-catenin in the Wnt signalling pathways, playing a key role in regulating cell adhesion and tumour proliferation. It is activated under stress in response to DNA damage and it phosphorylates p53 and MDM2 to regulate cell death or survival decisions. Multiple phosphorylation epitopes (pS379, pS403/404, pS409, pS410 and pS409/410) were identified in aggregated TDP-43 via phosphorylation-specific anti-TDP-43 antibodies. This abnormal phosphorylation and accumulation of TDP-43 is regulated by the protein-serine/threonine kinase casein kinase-1 (1). This description may include information annotated by UniProt and/or Google AI.